No Data
No Data
Yongan Pharmaceutical: 2024 Semi-Annual Report
Yongan Pharmaceutical: 2024 Semi-Annual Report Summary
qianjiang yongan pharmaceutical (002365.SZ) released its performance for the first half of the year, with a net income of 52.4852 million yuan, a decrease of 6.49%.
Qianjiang Yongan Pharmaceutical (002365.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
As of August 9, 2024, qianjiang yongan pharmaceutical (002365.SZ) had 26,513 shareholders.
Qianjiang Yongan Pharmaceutical (002365.SZ) stated on the investor interaction platform on August 16 that as of August 9, 2024, the number of shareholders in the company was 26,513.
Qianjiang Yongan Pharmaceutical (002365.SZ): Has repurchased 1.04% of the shares accumulated.
On August 1st, Gelonhui reported that Qianjiang Yongan Pharmaceutical (002365.SZ) has accumulated 3,072,650 shares of the company through centralized bidding by July 31, 2024, accounting for 1.04% of the company's total share capital. The highest fill price is 7.30 yuan/share, the lowest fill price is 6.90 yuan/share, and the total amount of the trade is 21,682,594.50 yuan (excluding transaction fees). The implementation of the company's share buyback plan complies with relevant laws and regulations and meets the company's established buyback plan.
Qianjiang Yongan Pharmaceutical (002365.SZ) has accumulated repurchased 1.04% of its shares.
On July 24th, Gelonhui reported that as of July 24th, 2024, Qianjiang Yongan Pharmaceutical (002365.SZ) had repurchased a total of 3,072,650 shares of the company through a repurchase special securities account through centralized bidding trading, accounting for 1.04% of the total share capital of the company, with a maximum transaction price of 7.30 yuan/share, a minimum transaction price of 6.90 yuan/share, and a total transaction amount of 21.68259 million yuan (excluding transaction fees).
No Data
No Data